Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fenofibrate 145 mg Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Fenofibric Acid Versus Tricor® (Fenofibrate)

NCT00961116
View directory record Official record
Conditions
Healthy
Interventions
Fenofibric Acid (Fibricor™) 105 mg Tablet, Fenofibrate (Tricor®) 145 mg Tablet
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2009 · Synced Nov 13, 2026, 3:16 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia

NCT01048502
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Fenofibrate (Tricor) tablets, Placebo, Lovaza
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Nov 13, 2026, 3:16 AM EST
Not listed Phase 4 Interventional Accepts healthy volunteers

Interrogating Fatty Acid Metabolism Impairment and Clinical Correlates in Males with Klinefelter Syndrome

NCT05498090
View directory record Official record
Conditions
Klinefelter Syndrome
Interventions
Fenofibrate 145 mg
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years to 40 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Nov 13, 2026, 3:16 AM EST
Completed Phase 2 Interventional

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

NCT00813527
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Lapaquistat acetate and fenofibrate, Fenofibrate
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
32
States / cities
Huntsville, Alabama • Sierra Vista, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Nov 13, 2026, 3:16 AM EST
Completed Phase 2 Interventional Results available

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

NCT04929379
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Fenofibrate, Placebo
Drug · Other
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 13, 2026, 3:16 AM EST
Completed Phase 2 Interventional Results available

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

NCT00559962
View directory record Official record
Conditions
Hyperlipidemia
Interventions
AEGR-733, placebo, AEGR-733 and atorvastatin, AEGR-733 and fenofibrate, AEGR-733 and ezetimibe
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Nov 13, 2026, 3:16 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Predictors of Response to Fenofibrate

NCT01023750
View directory record Official record
Conditions
Hypertriglyceridemia, Insulin Resistance
Interventions
Fenofibrate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Nov 13, 2026, 3:16 AM EST
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

NCT02781584
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
SEL, FIR, CILO, FENO, VAS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Chandler, Arizona • La Jolla, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Nov 13, 2026, 3:16 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation

NCT00470262
View directory record Official record
Conditions
Metabolic Syndrome X, Prediabetic State
Interventions
Fenofibrate 145mg PO QD, Pioglitazone 45 mg PO QD
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Nov 13, 2026, 3:16 AM EST
Completed Phase 2 Interventional Results available

FEnofibRate as a Metabolic INtervention for COVID-19

NCT04517396
View directory record Official record
Conditions
Covid19
Interventions
Fenofibrate/fenofibric acid, Placebo, Usual care
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Nov 13, 2026, 3:16 AM EST
Terminated Not applicable Interventional Results available

Effect of a Fibrate and a Statin on Endothelial Dysfunction

NCT00491400
View directory record Official record
Conditions
Diabetes Mellitus, Metabolic Syndrome
Interventions
Fenofibrate, Atorvastatin
Drug
Lead sponsor
Boston University
Other
Eligibility
30 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Nov 13, 2026, 3:16 AM EST
Completed Phase 2Phase 3 Interventional Results available

Fenofibrate Treatment in SCI

NCT02455336
View directory record Official record
Conditions
Spinal Cord Injury, Dyslipidemia
Interventions
Fenofibrate, No intervention
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 69 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Nov 13, 2026, 3:16 AM EST
Completed Phase 2 Interventional Results available

Medication Development in Alcoholism: Investigating PPAR Agonists

NCT02158273
View directory record Official record
Conditions
Alcoholism
Interventions
Sugar Pill, TRICOR (fenofibrate)
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Nov 13, 2026, 3:16 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

NCT00359281
View directory record Official record
Conditions
Healthy
Interventions
atorvastatin, simvastatin, ezetimibe, fenofibrate, dextromethorphan, Extended Release Niacin
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Nov 13, 2026, 3:16 AM EST
Completed No phase listed Observational Results available

Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate

NCT05080192
View directory record Official record
Conditions
Covid19
Interventions
Fenofibrate, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Nov 13, 2026, 3:16 AM EST
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)

NCT00819910
View directory record Official record
Conditions
Hypertriglyceridemia in Type 4 Hyperlipidemia, Non Diabetic Subjects With Normoglycemia
Interventions
Rosiglitazone, Placebo (Rosiglitazone), Placebo (Fenofibrate), Fenofibrate
Drug
Lead sponsor
Ahmad Slim
Federal
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Nov 13, 2026, 3:16 AM EST